See the DrugPatentWatch profile for Ganirelix
The generic name for Ganirelix is ganirelix [1].
What is Ganirelix used for?
Ganirelix is a synthetic decapeptide that is used to prevent premature ovulation in women undergoing controlled ovarian stimulation for assisted reproduction techniques, such as in vitro fertilization (IVF) [2]. It works by suppressing the surge of luteinizing hormone (LH), which can trigger ovulation [3].
How does Ganirelix work?
Ganirelix acts as a gonadotropin-releasing hormone (GnRH) antagonist. By binding to GnRH receptors in the pituitary gland, it blocks the action of endogenous GnRH. This prevents the surge of LH and follicle-stimulating hormone (FSH) that normally occurs mid-cycle, thereby delaying ovulation [3].
When does Ganirelix patent expiry occur?
Information regarding the specific patent expiry dates for Ganirelix is available through resources like DrugPatentWatch.com [4]. Patent expiries can be complex and may involve multiple patents covering different aspects of the drug, such as composition of matter, formulation, and method of use.
Can generic versions of Ganirelix be made?
Once the relevant patents expire and regulatory hurdles are cleared, generic versions of Ganirelix can be manufactured and marketed [4]. The availability of generic alternatives typically leads to lower drug prices.
What are the risks associated with Ganirelix?
Potential side effects of Ganirelix include nausea, headache, and reactions at the injection site [3]. It is important for patients to discuss any concerns with their healthcare provider.
Sources:
[1] https://www.rxlist.com/ganirelix-drug.htm
[2] https://www.drugs.com/mtm/ganirelix.html
[3] https://www.ncbi.nlm.nih.gov/books/NBK544307/
[4] https://drugpatentwatch.com/